KLK3 and prostate cancer: A post-hoc exploratory analysis of a study randomizing patients with biochemical recurrence after primary therapy for prostate cancer to either an LCD or diet as usual reported weight loss and improved PSA doubling time (PSADT) in those in the LCD group (30 vs. 13 months, p = 0.007) (143).